| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785777 | Cancer Treatment Reviews | 2018 | 25 Pages |
Abstract
Our analysis indicates an optimal therapeutic window within which Dtot, d and n can be safely adjusted. Owing to both the risks of uncertainty due to inclusion of trials with d up to 3.5â¯Gy, and the exploitation of different cell killing mechanisms associated to larger d, the extrapolation to extremely hypo-fractionated regimens is not warranted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Giorgio Arcangeli, Stefano Arcangeli, Valentina Pinzi, Michaela Benassi, Marcello Benassi, Lidia Strigari,